ETF Components for SPWO - SP Funds S&P World (ex-US) ETF


Below is a list of stocks held by this ETF. We only list holdings in the same market. If this is a global ETF, there may be additional components other than those listed here.

Holdings

Symbol Grade Price % Change Allocation
TSM B 2.19 15.19
NVO F 0.37 2.65
SAP B 1.32 1.80
PDD C -0.14 1.79
AZN F -7.22 1.65
NVS D -1.03 1.61
INFY D -0.05 1.58
JD C 0.43 1.22
UL D 0.57 1.15
BHP B 1.00 1.06
SNY D -0.19 0.87
VALE D 0.28 0.85
SHOP B 1.44 0.73
ABBV B 0.60 0.70
RELX C 1.81 0.67
GSK F 0.14 0.58
RIO B 0.75 0.53
CNI F 0.94 0.46
UMC F -1.56 0.35
WCN C 0.64 0.35
CHT D 1.08 0.33
BEKE B 1.76 0.31
LI D 2.72 0.31
GFI C 1.79 0.30
BGNE D 0.38 0.29
GOLD D -0.35 0.26
HLN D 0.10 0.26
WDS F 0.51 0.23
CPNG A 4.63 0.23
NOK B 0.86 0.22
ERIC B 0.48 0.21
SCCO B 2.43 0.19
RDY F -1.27 0.19
WIT B 1.40 0.19
ICLR F 3.48 0.16
PAC D 1.41 0.13
XPEV B 5.51 0.13
MMYT B 2.73 0.12
CHKP F 0.51 0.12
ARM C 2.27 0.12
JHX F 1.89 0.11
XRX F 0.95 0.11
SQM D -0.33 0.11
ASR F 0.61 0.11
HTHT C 1.22 0.11
BZ C 1.90 0.09
GGB F -0.32 0.09
KOF F 0.94 0.09
CYBR C 2.22 0.09
SNN F 1.11 0.08
VIPS C -0.07 0.07
PSO A 3.36 0.07
WIX B 1.46 0.07
NICE C 1.19 0.07
TS B 2.15 0.05

Recent News for SP Funds S&P World (ex-US) ETF & its Holdings

Date Stock Title
Nov 5 SNY Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say
Nov 5 AZN Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say
Nov 5 ARM Qualcomm Vs. Arm: Pre-Earnings Semiconductor Showdown
Nov 5 NVO Novo Nordisk signs $285m deal with Ascendis to create once-monthly GLP-1RA
Nov 5 NVO Novo Nordisk Q3 2024 Earnings Preview
Nov 5 PDD Decoding PDD Holdings's Options Activity: What's the Big Picture?
Nov 5 NVS Editas Q3 Loss Narrower Than Expected, Revenues Decrease Y/Y
Nov 5 NVO Hims & Hers will start selling a generic weight loss drug
Nov 5 RDY Dr. Reddy's Laboratories Limited 2025 Q2 - Results - Earnings Call Presentation
Nov 5 NVO Novo Nordisk Secures License for Ascendis Pharma's Obesity Drug Technology
Nov 5 NVO Novo Nordisk Q3 Preview: Will $285 Million Weight Loss Bet Offset Bearish Charts?
Nov 5 RDY Dr. Reddy’s Q2 & H1FY25 Financial Results
Nov 5 NVS Is Novartis (NVS) Stock Undervalued Right Now?
Nov 5 GFI Should Value Investors Buy Gold Fields Limited (GFI) Stock?
Nov 5 NVS Is Argenx (ARGX) Outperforming Other Medical Stocks This Year?
Nov 5 NVO Catalent misses Q1 revenue estimates ahead of $16.5 billion deal close with Novo Holdings
Nov 5 TSM Taiwan Semi CFO says power bill in Taiwan to rise faster than elsewhere
Nov 5 NVO Hims & Hers to launch a generic for Novo’s older GLP-1
Nov 5 CPNG Authentic Brands Pulls Reebok Europe License From New Guards Group
Nov 5 NVO Ascendis Pharma granted Novo exclusive worldwide license to TransCon platform
The Shariah World Index is designed to measure the performance of companies located in developed and emerging markets outside of the United States that pass rules-based screens for adherence to shariah investment guidelines, with a cap applied to ensure diversification among companies in the index. The fund is non-diversified.
Credit Diversification
Back to the Main SPWO Page...